See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

Can Enveric's Newly Patented Compounds Transform Addiction and ADHD Treatment? Patent Details Revealed

Summary by stocktitan.net
Enveric's patented mescaline derivatives show promising interaction with key brain receptors involved in opioid withdrawal, ADHD, anxiety, and depression treatment.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

All
Left
Center
Right
420 Intel420 Intel

EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD

EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD Image Cannabis News February 26, 2025 Enveric Biosciences has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, ADHD anxiety, and other neuropsychiatric disorders, potentially offering new therapeutic avenues for Medical Canna…

Read Full Article
Investing News NetworkInvesting News Network

Japan Patent Allowance for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce’s Anti-infectives, expiry 2041. The Japan Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably:Process for preparation of RECCE® anti-infectivesUse of R327/R529 for th…

Read Full Article
Microdose Psychedelic InsightsMicrodose Psychedelic Insights

Enveric Biosciences' Patent For Non-Hallucinogenic Psychedelic Compounds

In a significant development for mental health treatments, Enveric Biosciences (NASDAQ: ENVB) has secured its first U.S. patent for a novel series of compounds that could transform how we approach neuropsychiatric disorders. The company’s EVM401 Series represents a growing class of psychedelic-inspired therapies designed to provide the benefits of traditional psychedelics without the hallucinogenic effects that can limit their clinical use. Brea…

Read Full Article
stocktitan.netstocktitan.net

Can Enveric's Newly Patented Compounds Transform Addiction and ADHD Treatment? Patent Details Revealed

Enveric's patented mescaline derivatives show promising interaction with key brain receptors involved in opioid withdrawal, ADHD, anxiety, and depression treatment.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Tuesday, February 25, 2025.
Sources are mostly out of (0)

Similar News Topics

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal